RIBOZYME AND OMICS

ABOUT COMPANY

History

이미지

2017 - 2025

2025
05

Research Collaboration and License Agreement with Eli Lilly and Company

관련기사보기
02

Rznomics’ Liver Cancer Treatment Receives FDA Fast Track Designation

관련기사보기
2024
12

Rznomics Secures KRW 20.3 Billion in Pre-IPO Funding, Bringing Total Investment to KRW 81.2 Billion

관련기사보기
11

Awarded the Minister of Health and Welfare Commendation at the 2024 Health Industry Performance Exchange Meeting

관련기사보기
09

Rznomics identified as a national strategic technology possessing/managing company for advanced bio-gene and cell therapy

관련기사보기
09

Rznomics Wins the Korea Innovation Startup Award led by K-Deep Tech

관련기사보기
08

Rznomics gets approves U.S. FDA For anticancer Candidate Based On Gene Therapy

관련기사보기
07

RZ-004 gets Approves Australian Clinical Trial Plan for hereditary retinopathy

05

First Case in National Strategic Technology Verification System : Rznomics’ ‘RNA Gene Therapy'

관련기사보기
05

Selected as a company for a Deep tech Incubator Project for Startup

관련기사보기
01

Granted Orphan Drug Designation(ODD) from FDA for RZ-001(HCC)

관련기사보기
01

Clinical trial phase-1b/2a of RZ-001(HCC) Combination therapy approved by Korean MDFS

관련기사보기
2023
12

Selected as a support company for the Super Gap Startup Open Innovation Challenge

관련기사보기
11

US FDA Fast Track approval of RZ-001(GBM)

관련기사보기
10

Selected as one of the 50 Best Companies in Technology Development for Small and Medium-sized Businesses

관련기사보기
09

Wins Most Promising Gene Therapy Pipeline Award at Cell & Gene Therapy World Asia 2023(CGTWA 2023) for the second consecutive year

관련기사보기
05

Korean MDFS(Phase 1/2a) approval of RZ-001(GBM)

관련기사보기
05

US FDA IND(phase 1/2a) approval of RZ-001(GBM)

관련기사보기
2022
12

Selected as a military service-designated entities(research institute)

10

US FDA IND(phase 1/2a) approval of RZ-001(HCC)

관련기사보기
09

Wins Award for Promising Candidates for Genetic Therapy at International Events

관련기사보기
06

Series C funding complete

관련기사보기
06

Clinical test phase-1/2a of RZ-001 approved by Korean MDFS

관련기사보기
05

INNOBIZ Certification acquired

2021
11

Selected as the national new drug development project announced by Ministry of Science and ICT, Ministry of Trade, Industry, and Energy, Ministry of health and Welfare

관련기사보기
03

Bridge funding complete

관련기사보기
2020
12

Selected for Phase 2 of Innovativ drug pipeline discovery by the Ministry of Science and ICT

관련기사보기
11

Successful completion of TIPS program selected by Ministry of SMEs and Startups

01

Participate in Innovative drug pipeline project of Ministry of Science and ICT

2019
11

Head Office relocated from Gwangju to Yongin (Dankook Univ.)

10

Opening Ceremony of Rznomics Inc. (Oct 2, 2019)

09

Series A investment completed

관련기사보기
05

Selected for Innovative drug pipeline discovery project by the Ministry of Science and ICT

2018
05

Korean Venture Capital Association corporate certification and acquired (May 24, 2018)

05

Research Institute founded and certified (May 21, 2018)

2017
12

Seed& Pre-A investment completed (Dec 2017 / Jul 2018)

12

Selected TIPS program by the Ministry of SMEs and Startups (Dec 22, 2017)

11

Registered as R&D Special Zone (Gwangju Innopolis) Research Company (Nov 23, 2017)

08

Rznomics Inc. established (Aug 29, 2017)